NEW YORK, March 4, 2016 /PRNewswire/ -- Spheryx, Inc. announced today that their journal article entitled "Holographic Characterization of Protein Aggregates", was selected by the journal's Editoral Team to be displayed under Features on the editors of the Journal of Pharmaceutical Sciences' new website <http://www.jpharmsci.org>. Dr. Laura A. Philips, CEO, and Dr. David B. Ruffner, Director of Analytical Services, of Spheryx collaborated with Prof. David G. Grier and Prof. Michael D. Ward professors of physics and chemistry, respectively at New York University on the work presented in the paper. Prof. Grier is also a co-founder of Spheryx, and Chair of the Spheryx Scientific Advisory Board. Dr. Philips stated, "Being featured by the editors on the Journal's website is excellent exposure for the capabilities of Spheryx's patented Total Holographic Characterization™ in the detection and monitoring of protein aggregates."
About Spheryx, Inc.
Spheryx, Inc. is a privately held analytical services and instruments company providing Total Holographic Characterization™ of colloidal materials. Spheryx's breakthrough proprietary technology uses holographic video microscopy to characterize each particle in colloidal dispersions and multi-component colloidal mixtures, thereby offering unprecedented insights into these materials' characteristics. Applications include research and development, quality assurance and manufacturing process control across a broad spectrum of industries, where characterization of colloids can enhance innovation, improve safety and reduce costs. For more information please visit the company's website at http://www.spheryx.solutions/
Note: This news release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or result to differ materially. These risks and uncertainties include, among others: the results, timing and costs of our studies; our ability to obtain future funding on acceptable terms; the possible impairment of, or inability to obtain intellectual property rights; and innovation by our competitors.
Laura Philips, CEO
SOURCE Spheryx, Inc.